Joshua Resnick - 18 Jun 2026 Form 4 Insider Report for PepGen Inc. (PEPG)

Reporting relationship: Director
Issuer ticker: PEPG
Reported as of: 18 Jun 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 22 Jun 2026, 16:12:26 UTC
Prior SEC filing: 18 Jun 2026
Source filing: View source filing
Reporting owner signature: /s/ Noel Donnelly, as attorney-in-fact

Key filing fact

Joshua Resnick filed Form 4 for PepGen Inc. (PEPG) on 22 Jun 2026.

Key facts

This page summarizes Joshua Resnick's Form 4 filing for PepGen Inc. (PEPG).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 22 Jun 2026, 16:12.

Change

Previous filing in this sequence was filed on 18 Jun 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001690959 Primary reporting owner

Resnick Joshua

Relationship: Director
Address: C/O PEPGEN INC., 321 HARRISON AVE, 8TH FLOOR, BOSTON
Signature: /s/ Noel Donnelly, as attorney-in-fact
Signature date: 22 Jun 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

PEPG transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value
Shares: +34,000
Change %
Price: $0.000000^*
Shares after: 34,000
Date: 18 Jun 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 34,000
Exercise price: $1.79
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

This option shall vest in full upon the earlier of (i) the first anniversary of the date of grant or (ii) the date of the next Annual Meeting; provided, however, that all vesting shall cease if the individual ceases to serve as a director, unless the Board of Directors determines that the circumstances warrant continuation of vesting.

Footnote F2

Under the Reporting Person's arrangement with RA Capital Management, L.P. (the "Adviser"), the Reporting Person holds the stock option for the benefit of the RA Capital Healthcare Fund, L.P. (the "Fund"), RA Capital Nexus Fund II, L.P. (the "Nexus Fund II"), and a separately managed account (the "Account"). The Reporting Person is obligated to turn over to the Adviser any net cash or stock received upon exercise of the stock option, which will offset advisory fees owed by the Fund, the Nexus Fund II, and the Account to the Adviser. The Reporting Person therefore disclaims beneficial ownership of the stock option and underlying Common Stock.